angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
== Radiolabeled somatostatin receptor antagonists in Peptide Radionuclide Receptor Therapy (PRRT) == Somatostatin receptor antagonists are also being developed as therapeutic agents in peptide radionuclide receptor therapy (PRRT) due to the wider binding of antagonists compared to agonists. Research indicated the antagonist Lu-DOTA-JR11 showed higher tumor uptake, more double-strand breaks within tumor cells, longer adherence time to tumors and improved tumor-to-kidney dose ratio. Moreover, another study finds out that radioactive atom, terbium-161 (161Tb), that can release short-ranged electrons, can combine with somatostatin receptor antagonists which localize at the cell membrane, giving an alternative solution, rather than the currently clinically used lutetium-somatostatin receptor agonist, which localize at the cytoplasm and nucleus. Moreover, Tb-antagonist in vitro shows 102-fold more potent than Lu-antagonist in inhibiting tumor cell growth and prolonging survival of mice, which is trusted to be due to its high linear energy transfer. This result is further repeated and confirmed in vivo, showing the high potential and strengths of radiolabeled somatostatin receptor antagonists to treat neuroendocrine neoplasms.
Tetrabenazine was approved in 2000 for treatment of chorea in Huntington's disease in the EU, and in 2008 in the US. Although other drugs had been used "off label", tetrabenazine was the first approved treatment for Huntington's disease in the US. The compound has been known since the 1950s. In 2017, deutetrabenazine, a heavier form of tetrabenazine medication for the treatment of chorea in HD, was approved by the FDA. This is marketed as Austedo. Valbenazine (Ingrezza) was also approved by the FDA for the treatment of Huntington's disease chorea in 2023. Tetrabenazine, deutetrabenazine, and valbenazine are all vesicular monoamine transporter 2 (VMAT2) inhibitors, which work by depleting dopamine in the brain, lessening involuntary movements. These are the only drugs that have been approved specifically for Huntington's disease (namely the chorea associated with it). Other drugs that help to reduce chorea include antipsychotics and benzodiazepines. Hypokinesia and rigidity, especially in juvenile cases, can be treated with antiparkinsonian drugs, and myoclonic hyperkinesia can be treated with valproic acid. Tentative evidence has found ethyl eicosapentaenoic acid to improve motor symptoms at one year. Amantadine has also been used to treat chorea, but there is limited evidence for its safety and efficacy. Psychiatric symptoms can be treated with medications similar to those used in the general population.
=== Connective tissue theory === Various scientists and physicians have suggested that sCSFLs may be the result of an underlying connective tissue disorder affecting the spinal dura. It may also run in families and be associated with aortic aneurysms and joint hypermobility. Up to two thirds of those affected demonstrate some type of generalized connective tissue disorder. Marfan syndrome, Ehlers–Danlos syndrome, and autosomal dominant polycystic kidney disease are the three most common connective tissue disorders associated with sCSFLs. Roughly 20% of patients with a sCSFL exhibit features of Marfan syndrome, including tall stature, hollowed chest (pectus excavatum), joint hypermobility and arched palate. However, no other Marfan syndrome presentations are shown.
For McArdle disease (GSD-V), regular aerobic exercise utilizing "second wind" to enable the muscles to become aerobically conditioned, as well as anaerobic exercise that follows the activity adaptations so as not to cause muscle injury, helps to improve exercise intolerance symptoms and maintain overall health. Studies have shown that regular low-moderate aerobic exercise increases peak power output, increases peak oxygen uptake (VO2peak), lowers heart rate, and lowers serum CK in individuals with McArdle disease. Regardless of whether the patient experiences symptoms of muscle pain, muscle fatigue, or cramping, the phenomenon of second wind having been achieved is demonstrable by the sign of an increased heart rate dropping while maintaining the same speed on the treadmill. Inactive patients experienced second wind, demonstrated through relief of typical symptoms and the sign of an increased heart rate dropping, while performing low-moderate aerobic exercise (walking or brisk walking). Conversely, patients that were regularly active did not experience the typical symptoms during low-moderate aerobic exercise (walking or brisk walking), but still demonstrated second wind by the sign of an increased heart rate dropping. For the regularly active patients, it took more strenuous exercise (very brisk walking/jogging or bicycling) for them to experience both the typical symptoms and relief thereof, along with the sign of an increased heart rate dropping, demonstrating second wind.
Erythromycin 12 hydroxylase (EC 1.14.13.154, EryK) is an enzyme with systematic name erythromycin-D,NADPH:oxygen oxidoreductase (12-hydroxylating) . This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
=== Tastes Like America === In 2018, CKE resumed producing separate campaigns for their Hardee's and Carl's Jr. brands. For Hardee's, it started the Tastes Like America campaign with music by Big Wet. For this campaign, Hardee's restored its 1976 logo, now in white; however, the Happy Star still appears, replacing the A in "Tastes". The previous logo will also continue to be used as well.
Alongside the general election, voters were asked to participate in a referendum regarding a proposed rewrite of the country's 2017 Constitution. On election night, unofficial results reported by Al Jazeera indicated that more than 57 per cent of voters had supported the drafting of a new constitution. People's Party leader Natthaphong Ruengpanyawut acknowledged that the referendum appeared to have been approved and stated his party would respect the parliamentary process. The proposal was carried. According to the Election Commission, 21,621,638 voters (60.16 per cent) approved the drafting of a new constitution, 11,241,653 (31.28 per cent) rejected it and 3,074,330 (8.55 per cent) expressed no opinion, from 35,937,621 valid ballots. A further 932,583 ballots were rejected as invalid. Turnout in the referendum was 36,870,266, or 69.65 per cent, about 937,000 fewer ballots than were cast in the general election held the same day. Support was broadly spread, with 288 of the 400 constituencies recording a 'yes' vote above 70 per cent and only 38 recording a 'no' vote above 50 per cent, two of them in Buriram and the remaining 36 in the upper south.
==== Front end ==== Waste from the front end of the nuclear fuel cycle is usually alpha-emitting waste from the extraction of uranium. It often contains radium and its decay products. Uranium dioxide (UO2) concentrate from mining is a thousand or so times as radioactive as the granite used in buildings. It is refined from yellowcake (U3O8), then converted to uranium hexafluoride gas (UF6). As a gas, it undergoes enrichment to increase the U-235 content from 0.7% to about 4.4% (LEU). It is then turned into a hard ceramic oxide (UO2) for assembly as reactor fuel elements. The main by-product of enrichment is depleted uranium (DU), principally the U-238 isotope, with a U-235 content of ~0.3%. It is stored, either as UF6 or as U3O8. Some is used in applications where its extremely high density makes it valuable such as anti-tank shells, and on at least one occasion even a sailboat keel. It is also used with plutonium for making mixed oxide fuel (MOX) and to dilute, or downblend, highly enriched uranium from weapons stockpiles which is now being redirected to become reactor fuel.
== Engineering and computer science == Renewable energy target Renewable energy technology Resolution enhancement technology, image processing technology used to manipulate dot characteristics ret, return from subroutine instruction in the x86 assembly language Registered engineering technologist, former certification in Alberta, Canada Rehabilitation engineering technologist, a role in rehabilitation engineering Ret, a measurement of the resistance to evaporative heat loss
Sources: en.wikipedia.org
=== Protein === C3orf52 consists of a disordered region, a transmembrane region, and a major polyA site. The molecular weight is of 24.3 kDa. This protein is predicted to be localized primarily in the cytoplasm (94.1%), with specific localization to the endoplasmic reticulum (44.4%). The protein is associated with two distinct isoforms; isoform 1 is 250 amino acids long, while isoform 2 is 217 amino acids long. In human research, isoform 2 is the predominant variation found and is the most common focus for research on C3orf52. Compositional analysis has indicated that this protein is acidic in nature, with a predicted isoelectric point of 3.99. Additionally, results show a high-scoring transmembrane segment spanning amino acids 66 to 93, which is also among the protein's most hydrophobic segment. C3orf52 contains a repetitive four-amino acid motif, including a sequence reading "LELS" at amino acids 13-16 and repeating at positions 101–104, this region is not conserved among orthologs.
Topical preparations of zinc include those used on the skin, often in the form of zinc oxide. Zinc oxide is generally recognized by the FDA as safe and effective and is considered very photo-stable. Zinc oxide is one of the most common active ingredients formulated into a sunscreen to mitigate sunburn. Applied thinly to a baby's diaper area (perineum) with each diaper change, it can protect against diaper rash. Chelated zinc is used in toothpastes and mouthwashes to prevent bad breath; zinc citrate helps reduce the build-up of calculus (tartar). Zinc pyrithione is widely included in shampoos to prevent dandruff. Topical zinc has also been shown to effectively treat, as well as prolong remission in genital herpes.
== Chemistry == The original encoded sequence of TsPep2 consists of 68 amino acids processed in a mature peptide of 29 amino acids with a final molecular weight of 2993.59 Da. TsPep2 differs in the mature sequence from TsPep3 only in one amino acid and TsPep1 shows 58,6% of sequence homology with Tspep2 and TsPep3.
They have a cloaca into which the urinary and genital passages open, but not a swim bladder. Cartilaginous fish produce a small number of large, yolky eggs. Some species are ovoviviparous and the young develop internally but others are oviparous and the larvae develop externally in egg cases. The bony fish lineage shows more derived anatomical traits, often with major evolutionary changes from the features of ancient fish. They have a bony skeleton, are generally laterally flattened, have five pairs of gills protected by an operculum, and a mouth at or near the tip of the snout. The dermis is covered with overlapping scales. Bony fish have a swim bladder which helps them maintain a constant depth in the water column, but not a cloaca. They mostly spawn a large number of small eggs with little yolk which they broadcast into the water column.
=== Repetitions and sets === In strength training, an exercise is commonly performed several times in a row. Each performance is known as a repetition. Two or more repetitions make a set. For each repetition, a person moves through one or more stages of movement. This may involve an eccentric phase where a muscle lengthens, and a concentric phase where it shortens. Each phase is preceded by a preparatory and preloading phase, and followed by a recovery phase. For example, someone doing a press up exercise will position themselves on their hands and feet with their body straight. They then begin a repetition: they prepare to lower themselves, then they bend their arms and lower themselves (called the eccentric phase due to the lengthening of the triceps), they then stop themselves close to the floor and recover their energy- the recovery may be very briefly performed or may take longer depending on how tired they are. They then prepare to raise themselves making whatever adjustments to their position as they feel are needed and preloading themselves in terms of energy, they then straighten their arms and raise themselves (the concentric phase), and at the top of the movement they stop and recover- the recovery in this position is significantly greater than in the lower position. The repetition cycle is then repeated beginning with a new preparatory phase. For different exercises the cycle may alter but will always contain preparatory and recovery phases. Sets may also be performed multiple times with rest periods between them.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.